Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PHILIP A WALLER

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1588630578
CMS profile
162854
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,311.78

95 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,311.78 95

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PHILIP A WALLER

NPI 1588630578 · CMS profile ID 162854

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588630578?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PHILIP A WALLER, NPI 1588630578, CMS profile ID 162854. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588630578?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PHILIP A WALLER, NPI 1588630578, CMS profile ID 162854. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588630578?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PHILIP A WALLER, NPI 1588630578, CMS profile ID 162854, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1588630578?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

95 matching records · $1,311.78 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 95 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–95 of 95.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $20.7605/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673243753 CMS
Sobi, Inc $14.0205/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698100143 CMS
E.R. Squibb & Sons, L.L.C. $13.3205/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651425069 CMS
Amgen Inc. $14.2105/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662875119 CMS
AbbVie, Inc. $2.4805/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647814369 CMS
AbbVie, Inc. $20.5405/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647814371 CMS
Janssen Biotech, Inc. $7.2705/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658774515 CMS
Janssen Biotech, Inc. $2.0905/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658774507 CMS
Janssen Biotech, Inc. $1.2505/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658774511 CMS
AbbVie, Inc. $12.3905/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647814381 CMS
Amgen Inc. $28.6605/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662875123 CMS
Janssen Biotech, Inc. $15.1605/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658774503 CMS
Lilly USA, LLC $13.6105/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658080283 CMS
E.R. Squibb & Sons, L.L.C. $17.5604/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651425051 CMS
AbbVie, Inc. $16.3104/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647814367 CMS
E.R. Squibb & Sons, L.L.C. $6.8504/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651425049 CMS
AbbVie, Inc. $2.2604/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647814365 CMS
PFIZER INC. $6.5704/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673238701 CMS
AbbVie, Inc. $21.4604/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647814355 CMS
Amgen Inc. $13.0504/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662875117 CMS
Mallinckrodt Enterprises LLC $29.1104/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704790285 CMS
Novartis Pharmaceuticals Corporation $16.4404/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660145991 CMS
Janssen Biotech, Inc. $4.4104/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658774495 CMS
PFIZER INC. $13.8603/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673245069 CMS
E.R. Squibb & Sons, L.L.C. $8.6603/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651425047 CMS
Genentech USA, Inc. $18.3103/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681330265 CMS
PFIZER INC. $13.1203/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673236637 CMS
Janssen Biotech, Inc. $2.7303/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658774491 CMS
Janssen Biotech, Inc. $19.5303/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658774487 CMS
Novartis Pharmaceuticals Corporation $20.6202/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660145989 CMS
Mallinckrodt Enterprises LLC $33.8702/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704790283 CMS
PFIZER INC. $5.9502/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673237085 CMS
Janssen Biotech, Inc. $13.6302/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658774483 CMS
Genentech USA, Inc. $20.8402/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681304911 CMS
E.R. Squibb & Sons, L.L.C. $11.6602/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651425039 CMS
AbbVie, Inc. $14.6602/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647814353 CMS
Mallinckrodt Enterprises LLC $21.0802/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704790281 CMS
Janssen Biotech, Inc. $17.8702/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658774457 CMS
AbbVie, Inc. $13.7801/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647814351 CMS
GENZYME CORPORATION $19.6201/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694274317 CMS
PFIZER INC. $13.3701/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673234005 CMS
Genentech USA, Inc. $24.9001/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681305947 CMS
Novartis Pharmaceuticals Corporation $15.4901/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660146001 CMS
FIDIA PHARMA USA INC. $5.5301/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694980003 CMS
E.R. Squibb & Sons, L.L.C. $4.3101/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651425025 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,311.78 95
PY2020 $1,188.59 61
PY2021 $1,315.15 73
PY2022 $1,315.11 65
PY2023 $1,259.25 60
PY2024 $1,129.82 55
PY2025 $1,246.39 60

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,356,153.63 127
PY2024 Recipient $104.58 1
PY2024 Principal investigator $926,705.76 31
PY2023 Principal investigator $606,322.25 41
PY2022 Recipient $20.00 1
PY2022 Principal investigator $285,116.08 69
PY2021 Recipient $284.07 1
PY2021 Principal investigator $349,583.03 82
PY2020 Recipient $1,047.74 2
PY2020 Principal investigator $525,562.35 239
PY2019 Recipient $750.00 1
PY2019 Principal investigator $858,694.41 214

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

127 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,975.85 12/04/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202527404
Principal investigator 1 ABBVIE INC. $21,442.65 12/04/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202527656
Principal investigator 1 ABBVIE INC. $15,660.80 12/04/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202527658
Principal investigator 1 ABBVIE INC. $1,296.45 12/04/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202527660
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,412.45 12/01/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289144
Principal investigator 1 ARGENX US, INC. $1,613.00 11/20/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145045
Principal investigator 1 ARGENX US, INC. $5,323.00 11/20/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145048
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,412.45 11/18/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288377
Principal investigator 1 Novartis Pharmaceuticals Corporation $17.12 11/15/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190298548
Principal investigator 1 ABBVIE INC. $7,996.25 11/05/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202522373
Principal investigator 1 ABBVIE INC. $5,451.60 11/05/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202522375
Principal investigator 1 ABBVIE INC. $7,737.86 11/05/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202522377
Principal investigator 1 GlaxoSmithKline, LLC. $2,370.60 11/05/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192156889
Principal investigator 1 ABBVIE INC. $3,850.35 11/04/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202520649
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,701.00 10/16/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190298553
Principal investigator 1 ABBVIE INC. $110.46 10/14/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202516643
Principal investigator 1 ABBVIE INC. $200.00 10/09/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202514333
Principal investigator 1 ARGENX US, INC. $576.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145026
Principal investigator 1 ARGENX US, INC. $576.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145029
Principal investigator 1 ARGENX US, INC. $576.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145033
Principal investigator 1 ARGENX US, INC. $576.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145036
Principal investigator 1 ARGENX US, INC. $576.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145041
Principal investigator 1 ARGENX US, INC. $5,289.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145054
Principal investigator 1 ARGENX US, INC. $5,323.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145059
Principal investigator 1 GlaxoSmithKline, LLC. $2,352.60 10/02/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192185306
Principal investigator 1 Eli Lilly and Company $10,000.00 09/16/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187875753
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,159.97 09/11/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190298557
Principal investigator 1 ABBVIE INC. $10,546.50 09/04/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202509064
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,470.00 08/21/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment No dispute reported 06/30/2026 1190298544
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $36,250.40 08/14/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) No dispute reported 06/30/2026 1225336021
Principal investigator 1 ARGENX US, INC. $576.00 08/13/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145268
Principal investigator 1 ABBVIE INC. $10,000.00 08/06/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202502552
Principal investigator 1 ABBVIE INC. $4,663.00 08/06/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202502554
Principal investigator 1 ABBVIE INC. $1,257.45 08/05/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202501354
Principal investigator 1 ABBVIE INC. $615.00 08/05/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501356
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/01/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192185309
Principal investigator 1 Eli Lilly and Company $40.00 07/31/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874193
Principal investigator 1 ARGENX US, INC. $1,613.00 07/25/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145256
Principal investigator 1 ARGENX US, INC. $1,613.00 07/25/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145260
Principal investigator 1 ARGENX US, INC. $3,044.00 07/25/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145264
Principal investigator 1 GlaxoSmithKline, LLC. $3,186.90 07/02/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192185313
Principal investigator 1 ARGENX US, INC. $37.60 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145270
Principal investigator 1 ARGENX US, INC. $286.50 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145273
Principal investigator 1 ARGENX US, INC. $35.80 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145275
Principal investigator 1 ARGENX US, INC. $18.80 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145278
Principal investigator 1 ARGENX US, INC. $39.75 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145283
Principal investigator 1 ARGENX US, INC. $2.45 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145286
Principal investigator 1 ARGENX US, INC. $2.80 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145290
Principal investigator 1 ARGENX US, INC. $79.50 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145294
Principal investigator 1 ARGENX US, INC. $238.75 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145297
Principal investigator 1 Eli Lilly and Company $104,547.00 06/24/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187875683
Principal investigator 1 ARGENX US, INC. $1,540.00 06/23/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144990
Principal investigator 1 ARGENX US, INC. $903.70 06/23/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145002
Principal investigator 1 ARGENX US, INC. $3,148.70 06/23/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145005
Principal investigator 1 ARGENX US, INC. $5,782.00 06/23/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145009
Principal investigator 1 ARGENX US, INC. $1,659.00 06/23/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145014
Principal investigator 1 ARGENX US, INC. $4,089.00 06/23/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145018
Principal investigator 1 ARGENX US, INC. $26.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145063
Principal investigator 1 ARGENX US, INC. $1.75 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145067
Principal investigator 1 ARGENX US, INC. $2.80 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145071
Principal investigator 1 ARGENX US, INC. $132.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145075
Principal investigator 1 ARGENX US, INC. $75.20 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145080
Principal investigator 1 ARGENX US, INC. $107.40 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145084
Principal investigator 1 ARGENX US, INC. $214.80 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145089
Principal investigator 1 ARGENX US, INC. $35.80 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145094
Principal investigator 1 ARGENX US, INC. $238.75 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145098
Principal investigator 1 ARGENX US, INC. $477.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145101
Principal investigator 1 ARGENX US, INC. $191.00 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145106
Principal investigator 1 ARGENX US, INC. $668.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145110
Principal investigator 1 ARGENX US, INC. $477.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145113
Principal investigator 1 ARGENX US, INC. $5.25 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145117
Principal investigator 1 ARGENX US, INC. $3.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145121
Principal investigator 1 ARGENX US, INC. $155.25 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145124
Principal investigator 1 ARGENX US, INC. $21.35 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145128
Principal investigator 1 ARGENX US, INC. $85.40 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145132
Principal investigator 1 ARGENX US, INC. $85.40 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145136
Principal investigator 1 ARGENX US, INC. $1.40 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145140
Principal investigator 1 ARGENX US, INC. $5.60 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145144
Principal investigator 1 ARGENX US, INC. $77.40 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145149
Principal investigator 1 GlaxoSmithKline, LLC. $2,447.10 06/04/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192185302
Principal investigator 1 ABBVIE INC. $1,402.05 06/03/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202488883
Principal investigator 1 ABBVIE INC. $1,296.45 06/03/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202488885
Principal investigator 1 ABBVIE INC. $12,200.00 06/03/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202488887
Principal investigator 1 ARGENX US, INC. $1,451.70 05/19/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144998
Principal investigator 1 GlaxoSmithKline, LLC. $2,352.60 05/09/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192156885
Principal investigator 1 SANOFI US SERVICES INC. $5,597.91 05/08/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1226090051
Principal investigator 1 ABBVIE INC. $3,543.90 05/06/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481973
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $460.00 04/28/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527471
Principal investigator 1 ARGENX US, INC. $4,089.00 04/25/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144984
Principal investigator 1 ARGENX US, INC. $4,475.00 04/25/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144987
Principal investigator 1 ARGENX US, INC. $1,659.00 04/25/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144995
Principal investigator 1 ARGENX US, INC. $233.00 04/25/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145021
Principal investigator 1 Eli Lilly and Company $756.00 04/23/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187873199
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $1,345.00 04/14/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527483
Principal investigator 1 ABBVIE INC. $12,500.00 04/03/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202469261
Principal investigator 1 ABBVIE INC. $1,538.25 04/03/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202469269
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $95.00 03/27/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527465
Principal investigator 1 Eli Lilly and Company $4,831.55 03/25/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187875745
Principal investigator 1 ARGENX US, INC. $1,248.00 03/24/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145237
Principal investigator 1 ARGENX US, INC. $1,800.00 03/24/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145242
Principal investigator 1 ARGENX US, INC. $2,034.00 03/24/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145246
Principal investigator 1 ARGENX US, INC. $8,000.00 03/24/2025 Non-covered Recipient Entity
Accurate Clinical Research Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237145252
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $90.00 03/17/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527475
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $810.00 03/17/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527479
Principal investigator 1 GlaxoSmithKline, LLC. $3,168.90 03/07/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192156881
Principal investigator 1 ABBVIE INC. $50.00 03/06/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202458416
Principal investigator 1 ABBVIE INC. $80.60 03/06/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202458419
Principal investigator 1 ABBVIE INC. $1,538.25 03/06/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202458423
Principal investigator 1 ABBVIE INC. $50.00 03/06/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202458427
Principal investigator 1 Eli Lilly and Company $1,854.67 02/25/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187875063
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 02/25/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223275537
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $95.00 02/24/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527488
Principal investigator 1 AstraZeneca UK Limited $35,829.90 02/12/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185538166
Principal investigator 1 Eli Lilly and Company $57,998.00 02/11/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187871907
Principal investigator 1 Eli Lilly and Company $153.00 02/10/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874195
Principal investigator 1 GlaxoSmithKline, LLC. $6,355.80 02/05/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192185327
Principal investigator 1 Vertex Pharmaceuticals Incorporated $17,331.37 01/31/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH HOUSTON
A Randomized, Double-blind, Placebo-controlled Study of ALPN-101 in Systemic Lupus Erythematosus No dispute reported 06/30/2026 1214123322
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,868.92 01/30/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
An Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab Infusion in Adults With Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190308016
Principal investigator 1 Eli Lilly and Company $3,551.58 01/27/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187875743
Principal investigator 1 Eli Lilly and Company $9,377.00 01/21/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187871909
Principal investigator 1 Eli Lilly and Company $109,221.00 01/21/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187873197
Principal investigator 1 Novartis Pharmaceuticals Corporation $250,917.66 01/21/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190308014
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,310.60 01/14/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190308012
Principal investigator 1 GlaxoSmithKline, LLC. $1,181.70 01/08/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192185317
Principal investigator 1 Novartis Pharmaceuticals Corporation $421,891.76 01/06/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment No dispute reported 06/30/2026 1190308010
Principal investigator 1 ABBVIE INC. $2,064.90 01/02/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202434202
Principal investigator 1 ABBVIE INC. $2,553.90 01/02/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202434260